No Data
Lukang Pharmaceutical Unit Gets China Approval for Type 2 Diabetes Drug
Shandong Lukang PharmaceuticalLtd (SHSE:600789) Stock Performs Better Than Its Underlying Earnings Growth Over Last Year
Lukang Pharmaceutical: Announcement of pre-increase in 2024 annual results of Lukang Pharmaceutical
Lukang Pharmaceutical 2024 Annual Results Advance Announcement
Shandong Lukang Pharmaceutical (600789.SH) issued a positive earnings forecast, expecting a net income of 0.35 billion yuan to 0.415 billion yuan for the year 2024, an increase of 42% to 69% year-on-year.
Shandong Lukang Pharmaceutical (600789.SH) announced that the company expects to achieve a net profit attributable to the parent company in the fiscal year 2024...
Shandong Lukang Pharmaceutical (600789.SH): Ezetimibe tablets have obtained the Pharmaceutical registration certificate.
On January 22nd, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced the receipt of the "Drug Registration Certificate" issued by the National Medical Products Administration for Ezetimibe Tablets. Ezetimibe reduces cholesterol levels in the blood by inhibiting the absorption of cholesterol in the small intestine, can attach to the brush border of the intestinal villi, inhibit cholesterol absorption, thereby reducing the transport of cholesterol from the small intestine to the liver, leading to a decrease in hepatic cholesterol stores and an increase in the clearance of cholesterol from the blood. This pharmaceutical can be used to treat primary hypercholesterolemia and can serve as an adjunct therapy beyond dietary control, used alone or in combination with other treatments.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
